A metabolic crosstalk between liposarcoma and muscle sustains tumor growth.

Archive ouverte

Manteaux, Gabrielle | Amsel, Alix | Riquier-Morcant, Blanche | Prieto Romero, Jaime | Gayte, Laurie | Fourneaux, Benjamin | Larroque, Marion | Gruel, Nadège | Quignot, Chloé | Perot, Gaelle | Jacq, Solenn | Cisse, Madi | Pomiès, Pascal | Sengenes, Coralie | Chibon, Frédéric | Heuillet, Maud | Bellvert, Floriant | Watson, Sarah | Carrere, Sebastien | Firmin, Nelly | Riscal, Romain | Linares, Laetitia

Edité par CCSD ; Nature Publishing Group -

International audience. Dedifferentiated and Well-differentiated liposarcoma are characterized by a systematic amplification of the Murine Double Minute 2 (MDM2) oncogene. We demonstrate that p53-independent metabolic functions of chromatin-bound MDM2 are exacerbated in liposarcoma and mediate an addiction to serine metabolism to sustain tumor growth. However, the origin of exogenous serine remains unclear. Here, we show that elevated serine levels in mice harboring liposarcoma-patient derived xenograft, released by distant muscle is essential for liposarcoma cell survival. Repressing interleukine-6 expression, or treating liposarcoma cells with Food and Drugs Administration (FDA) approved anti-interleukine-6 monoclonal antibody, decreases de novo serine synthesis in muscle, impairs proliferation, and increases cell death in vitro and in vivo. This work reveals a metabolic crosstalk between muscle and liposarcoma tumor and identifies anti-interleukine-6 as a plausible treatment for liposarcoma patients.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion